Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 8/20 | 0.47 |
| ▸ | PREP | P48147 | 8/20 | 0.47 |
| ▸ | DPP4 | P27487 | 10/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15765611 | 1.00 | FAP (0.47) | FAPPREPDPP4DPP7KMT2A | |
| SCHEMBL10117317 | 1.00 | FAP (0.47) | FAPPREPDPP4DPP7KMT2A | |
| SCHEMBL23314866 | 0.85 | MEN1 (0.51) | FAPPREPDPP4KMT2ASMN1; SMN2 | |
| SCHEMBL1633733 | 0.85 | MEN1 (0.51) | FAPPREPDPP4KMT2ASMN1; SMN2 | |
| SCHEMBL8350270 | 0.81 | PREP (0.48) | FAPPREPDPP4DPP7DPP8 | |
| SCHEMBL8253564 | 0.81 | DPP4 (0.44) | FAPPREPDPP4DPP7DPP8 | |
| SCHEMBL8350007 | 0.81 | ACE (0.51) | FAPPREPDPP4 | |
| SCHEMBL18636997 | 0.81 | ACE (0.51) | FAPPREPDPP4 | |
| SCHEMBL8350809 | 0.81 | POLB (0.49) | FAPPREPDPP4DPP7SMN1; SMN2 | |
| SCHEMBL12824557 | 0.80 | PREP (0.43) | FAPPREPDPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678334-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2017-03-22 | — | — | EP | disclosed |
| US-20120115918-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115918-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | FAP 2726/4885PREP 1022/4885DPP4 159/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | FAP 2726/4885PREP 1022/4885DPP4 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.